Recon: Philippines Considers Reviving Use of Sanofi Dengue Vaccine

• PhRMA’s top lobbyist will leave at the end of August (STAT)
• A Blood Test for Alzheimer’s? It’s Coming, Scientists Report (NYTimes)
• Federal judge allows pharma to proceed with lawsuit against California transparency law (STAT)
• BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end (Fierce) (Endpoints)
• Clovis dives as investor pessimism reaches 'unprecedented levels' (BioPharmaDive)
• Congress is going after drug prices. Pharma CEOs aren't panicking, yet (BioPharmaDive)
• A few questions on importation (Politico)

• Salk scientists create the world’s first human/monkey chimeras in China — cue the controversy (Endpoints)
• Philippines weighs re-use of controversial dengue vaccine (Reuters)
• Phase 3 trial of Transgene's oncolytic virus halted for futility (Fierce) (Press)
• Nucala receives self-administration EU approval (PharmaTimes)
• Rakuten Medical reels in another megaround to fund cancer R&D (Fierce) (Endpoints)
• Fujifilm pays Biogen nearly $1B for Denmark biologics site  (Fierce)
• Boehringer posts solid first half as business revamp beds in (PMLive)
• Still no ferry contracts for no-deal Brexit medicines supplies (PMLive)
• How Will You Spend Extra £434m On No-Deal Brexit Planning? Industry Asks UK Gov’t (Pink Sheet-$)
• Saudi Arabia backs $550 million investment in health start-up Babylon, valuing it at $2 billion (CNBC)
• Congo’s Ebola Outbreak Isn’t Just Congo’s Problem (Bloomberg)
• Pandemic bonds face scrutiny after Ebola outbreak yet to trigger payout (Reuters)
• Fourth Ebola case found in Congo city, raising fears of faster spread (Reuters)
• Rwanda says its border with Congo remains open (Reuters)
• Fear, violence and distrust hamper U.S. involvement in Ebola outbreak (NBC)

• Will The Pfizer-Mylan Deal Face Antitrust Hurdles? (Pink Sheet-$)
• FDA FY2020 User Fee Table (Focus)
• Takeda staffers accuse drugmaker of favoring Shire employees during merger: report (Fierce) (Korea Biomed)
• Biosimilars: Rise In US FDA Approvals Means Lower Or Flat User Fees In FY 2020 (Pink Sheet-$)
• PDUFA Application Fee Nears $3m Threshold In FY 2020 (Pink Sheet-$)
• Radiopharmaceuticals: FDA Finalizes Guidance on Nonclinical Studies, Labeling (Focus)
• Regenxbio inks viral vector rights deal with Pfizer (BioPharmaDive)
• Enhancing CAR-T cell activity (Nature)
• Everything Old is New Again: FDA Revises its 2014 Rare Pediatric Disease Priority Review Voucher Guidance for Industry (FDA Law Blog)
• Janssen returns rights for experimental cancer immunotherapy to Alligator Bioscience, sending shares spiraling by 40% (Pharmafile)
• A watchdog group sets aside emotions to assess drugs’ value. Patients say their lives are more than a number (STAT)
• Backed by Novo and Orbimed, Thierry Abribat hauls in $75M for biotech #3 — a transatlantic upstart focused on rare diseases (Endpoints)
• Using a more diverse microbiome, scientists look to create a better lab mouse (STAT)
• Could stem cell transplants make BMS' checkpoint inhibitors work in resistant lymphoma? (Fierce)
• Pharmacy groups seek to break an impasse over FDA framework for monitoring compounders (STAT)
• Experimental treatment slows prion disease, extends life of mice (NIH)
• Regenerative medicine companies raised $4.8B in first half of 2019 (Medcity)
• Indivior Submits Products For Approval Outside The US, Where Pressures Mount (Scrip-$)

• FDA Updates Guidance on Devices in the Magnetic Resonance Environment (Focus)
• B. Braun wins breakthrough nod for drug-coated balloon catheter (MassDevice)
• Bio-Rad beats expectations on Q2 results (MassDevice)
• Teleflex stock up on Street-beating Q2 earnings (MassDevice)
• Hillrom to pay $130m for Breathe Technologies as fiscal Q3 numbers top forecast (MassDevice)
• Fulgent Gets NY State Clinical Lab Permit, Approval to Offer Genetic Tests (GenomeWeb)
• Class 1 Device Recall FilterTips (1500 ul) used with QIAsymphony SP/AS Instruments (FDA)

• From Budget Deal to FY 20 Appropriations: Reasons for Optimism? (Alliance for a Stronger FDA)
• CBD Piques the Interest of Consumer Health Giants (Bloomberg)
• Canadian pot company Cronos gets foothold in US by buying popular CBD beauty brand Lord Jones (CNBC)
• Inside Stephen Miller's push to change 'public charge' rule (Politico)
• Fed. Circ. Design Patent Case Can Guide Medical Device Cos. (Law360-$)
• AVX Can't Shake Greatbatch's $22M Pacemaker Patent Win (Law360-$)
• CRISPR Interference Parties Propose Motions (Patent Docs)
• Excellent Infuse Preemption Decision out of Eastern District of Michigan (Drug & Device Law)

• FDA Advisory Committee Calendar

• EU Regulatory Roundup: Regulatory Action Against Fresenius Kabi's Calea Affects UK Product Supply (Focus)
• NICE backs Bayer’s Xarelto (PharmaTimes)
• Top UK doctors warn Boris Johnson that no-deal Brexit would cause key cancer therapy supply shortages (Pharmafile)
• Superbugs found lurking in London underground and hospitals (Reuters)
• NICE recommends aspirin for cancer prevention for the first time (Pharmaceutical Journal)
• Consultation on guidance on the safe use of bed rails (MHRA)
• Toward a Just and Learning Culture in the NHS (Harvard Bill of Health)

• Move over, Hong Kong: Shanghai’s new tech board sees fervent demand for maiden biotech IPO (Endpoints)

• Allergan macro-textured breast implants and tissue expanders (TGA)

• Poll Finds Trust In Science Is Rising (NPR)
• If you smoke pot, your anesthesiologist needs to know (NBC)
• Population and the Environment — Time for Another Contraception Revolution (NEJM)